- Home
- About us
- Products
- Bioreactors and Fermentors Cell Culture Fermenter Fermentor Bioreactor
- Other Bioprocess Equipment Automatic Fermenter Bioreactor 100l Fermenter bacteria Bioreactor
- Mammalian Cell Bioreactor 200l Bioreactor Stainless Steel Bioreactor bioreactor Fermenter
- Lab Fermenter Bioreactor Industrial Stainless Steel Fermenter
- Vaccine Fermenter(GMP) Fermentation Equipment stainless Steel Bioreactor
- Mini Lab Glass Fermenter Magnetic Mixing Cell Culture Fermenter Bioreactor
- CIP Station Automatic Bioreactor Fermenter
- Faqs
- News
- Certificate
- Contact us
From being stuck in the neck to overtaking on the bend, China's 70% domestic production rate of bioreactors is causing multinational giants to "exit"!
time2025/02/13
- In recent years, with the changes in the international trade environment and the upgrading of the biopharmaceutical industry, the domestic substitution process of bioreactors, the core equipment of biopharmaceuticals, has accelerated.
From relying on imports to gradually breaking overseas monopolies, a large number of domestic enterprises are reshaping the industry landscape through technological breakthroughs and cost advantages.
1、 Progress in domestic substitution: from "following" to "surpassing"
Stainless steel reactor: The localization rate exceeds 70%, and multinational giants have "withdrawn".
According to the latest data in 2024, the localization rate of stainless steel bioreactors has jumped from about 30% in 2022 to 70% -80%. Multinational companies such as Sartorius are gradually reducing their market share in China.
This is thanks to the breakthroughs made by domestic manufacturers in technological maturity (such as process amplification and flow field simulation) and supply chain stability.
Bailun Biotechnology is continuously replacing imported equipment through independent research and development and project experience accumulation.
Disposable reactor: domestication rate exceeds 50%, key technology catching up
Disposable bioreactors are widely used in research and small-scale production due to their high flexibility and low pollution risk. Although its localization rate has increased from less than 20% in 2022 to the current 50% -60%, core consumables such as reaction bags and film materials still rely on imports.
However, leading companies have already achieved specialized membrane patent layout, while some companies are narrowing the gap in areas such as agitator design and automatic control.
2、 Cost advantage: Prices as low as one-third of imports, driving pharmaceutical companies to 'switch'
Currently, the price of domestically produced bioreactors is generally half or even one-third of that of imported products.
In some cases, the price of stainless steel reactors of the same specifications is 30% lower than overseas, while the price of domestic equipment for disposable reactors is only 65% of imported equipment, and the cost of consumables is as low as 30% -50%.
This advantage directly reduces the pressure on fixed assets investment of pharmaceutical enterprises, especially cost sensitive SMEs.
3、 Industrial safety: preventing the "decoupling and chain breaking" of bioreactors
On the other hand, in the context of the China US trade friction, supply chain security has become a core concern for pharmaceutical companies.
Domestic equipment not only has a short supply cycle, but also can quickly respond to customized needs, avoiding production interruptions caused by overseas supply disruptions.
At the same time, policies such as the "14th Five Year Plan" for the development of the pharmaceutical industry clearly support the localization of high-end pharmaceutical equipment, further catalyzing the process of substitution.
Chinese bioreactors are accelerating their global expansion!
4、 Technological Breakthrough: From "Imitation" to "Innovation"
Currently, a large number of bioreactor enterprises have accumulated multiple patents in key fields such as flow field simulation (CFD) and process analysis technology (PAT) through independent research and development and university cooperation.
Bailun Biotechnology has made progress in the development of large-scale cell culture reactors, and its technology level for process amplification is steadily improving.
5、 Looking to the future: Core components still need to be tackled
Despite the rapid progress of domestic substitution, key components such as high-end sensors and precision valves still rely on imports.
In addition, concerns about equipment stability from pharmaceutical companies, such as the risk of batch failure caused by reactor replacement, still need to be resolved through long-term validation.
However, the industry generally believes that the trend of substitution is irreversible. With the influx of capital and deepening cross-border cooperation, domestic bioreactors are expected to achieve full industry chain autonomy and controllability within 5-10 years.
On the third day of the Lunar New Year, I asked DeepSeek to list the most outstanding bioreactor manufacturing companies in China!
Conclusion: Starry Sky and Ocean, Promising Future
The rise of domestic bioreactors, from being "neck tied" to "running and surpassing", is not only a microcosm of technological breakthroughs, but also an inevitable upgrade of China's high-end manufacturing.
With the domestic equipment such as Bailun bioreactor, the global competitive landscape will be reshaped in multiple dimensions such as cost, service, and greenization.
This wave of substitution will ultimately help China's biopharmaceutical industry sail towards a broader sea of stars!
